Search research articles
Contact Us
Filters
Showing results (71-80 of 78) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 78 results.
Clinical Genitourinary Cancer
|
May 4, 2025
Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study
Colin Williams, Andrisha-Jade Inderjeeth, Wei Hong, et al.
JCO Oncology Practice
|
June 16, 2023
Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations
Ciara Conduit, Jeremy Lewin, Andrew Weickhardt, et al.
European Urology Oncology
|
January 31, 2023
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Viktor Grünwald, Thomas Powles, Evgeny Kopyltsov, et al.
Asia-Pacific Journal of Clinical Oncology
|
January 29, 2026
Extracranial, Extragonadal Germ Cell Tumors: A Multicenter Australian Case Series
Kar Ven Cavan Chow, Ciara Conduit, Sophie O'Haire, et al.
The Journal of Antimicrobial Chemotherapy
|
November 18, 2024
Parenteral aciclovir for suspected herpes simplex virus infection in children: 0-18 years
Angela Berkhout, Julia E Clark, Cheryl A Jones, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
December 21, 2022
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Amanda Pereira-Salgado, Angelyn Anton, Fanny Franchini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Robert J Motzer, Camillo Porta, Masatoshi Eto, et al.
The New England Journal of Medicine
|
February 22, 2021
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer, Boris Alekseev, Sun-Young Rha, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 78) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 78 results.
Clinical Genitourinary Cancer
|
May 4, 2025
Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study
Colin Williams, Andrisha-Jade Inderjeeth, Wei Hong, et al.
JCO Oncology Practice
|
June 16, 2023
Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations
Ciara Conduit, Jeremy Lewin, Andrew Weickhardt, et al.
European Urology Oncology
|
January 31, 2023
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Viktor Grünwald, Thomas Powles, Evgeny Kopyltsov, et al.
Asia-Pacific Journal of Clinical Oncology
|
January 29, 2026
Extracranial, Extragonadal Germ Cell Tumors: A Multicenter Australian Case Series
Kar Ven Cavan Chow, Ciara Conduit, Sophie O'Haire, et al.
The Journal of Antimicrobial Chemotherapy
|
November 18, 2024
Parenteral aciclovir for suspected herpes simplex virus infection in children: 0-18 years
Angela Berkhout, Julia E Clark, Cheryl A Jones, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
December 21, 2022
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Amanda Pereira-Salgado, Angelyn Anton, Fanny Franchini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Robert J Motzer, Camillo Porta, Masatoshi Eto, et al.
The New England Journal of Medicine
|
February 22, 2021
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer, Boris Alekseev, Sun-Young Rha, et al.
Page
of 8